Icon

ALUNBRIG - (30MG, 90MG, 180MG)

BRIGATINIB None
30MG, 90MG, 180MG
Less Than $1000 mn
None None
None None
None None
ALUNBRIG is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
Yes
ALUNBRIG Patent 1 Patent 2 Patent 3 Patent 4
*** *********

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.